Intracerebral recombinant HSV-1 vector does not reactivate latent HSV-1

Gene Therapy

Volumn 4, Issue 12, 1997, Pages 1300-1304

  Wang, Q ^a   Guo, J ^a   Jia, W ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Brain; Herpes simplex virus; Latency; Reactivation; Ribonucleotide reductase; Thymidine kinase

Indexed keywords

CADMIUM SULFATE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; EXPRESSION VECTOR; EYE; HERPES SIMPLEX VIRUS 1; LATENT VIRUS INFECTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRIGEMINUS GANGLION; VIRUS ACTIVATION; VIRUS RECOMBINANT; VIRUS SHEDDING;

ANIMALIA; HERPES; HUMAN HERPESVIRUS 1;

EID: 0031452394     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300535     Document Type: Article

References (30)

1. Cook M, Bastone V, Stevens J. Evidence that neurons harbour latent herpes, simplex virus. Infect Immunol 1974; 9: 946-951.
2. Stevens J et al. RNA complementary to a herpes virus alpha gene mRNA is prominent in latently infected neurons. Science 1987; 235: 1056-1059.
3. Stevens J et al. Prominence of the herpes simplex virus latency-associated transcript in trigeminal ganglia from seropositive humans. J Infect Dis 1988; 158: 117-123.
4. Blondeau J, Aoki F, Blavin G. Stress-induced reactivation of latent herpes simplex virus infection in rat lumbar dorsal root gangha. J Psychosom Res 1993; 37: 843-849.
5. Schmidt D et al. Stress as a precipitating factor in subjects with recurrent herpes labialis. J Fam Pract 1985; 20: 359-366
6. Blyth W, Hill T, Field H, Harbour D. Reactivation of herpes simplex virus infection by ultraviolet light and possible involvement of prostaglandins. J Gen Virol 1976; 33: 547-550.
7. Blyth W, Harbour D, Hill T. Effect of immunosuppression on recurrent herpes simplex in mice. Infect Immun 1980; 29: 902-907.
8. Underwood G, Weed S. Recurrent cutaneous herpes simplex in hairless mice. Infect Immun 1974; 10: 471-474.
9. Warren S, Carpenter C, Boak R Symptomatic herpes, a sequela of artificially induced fever Incidence and clinical aspects, recovery of a virus from herpetic vesicles, and comparison with a known strain of herpes virus. J Exp Med 1940; 71: 155-168.
10. Sawtell N, Thompson R. Rapid in vivo reactivation of herpes simplex virus in latently infected murine ganglionic neurons after transient hyperthermia J Virol 1992; 66: 2150-2156.
11. Laycock K et al. The role of nerve growth factor in modulating herpes simplex virus reactivation in vivo. Graefes Arch Clin Exp Ophthal 1994; 232: 421-425.
12. Wilcox CL, Johnson EJ. Nerve growth factor deprivation results in the reactivation of latent herpes simplex virus in vitro, J Virol 1987; 61: 2311-2315.
13. Carton C, Kilbourne E. Activation of latent herpes simplex by trigeminal sensory-root section. New Engl J Med 1952; 246: 172-176.
14. Walz M, Price R, Notkins A. Latent ganglionic infection with herpes simplex virus types 1 and 2: viral reactivation in vivo after neurectomy. Science 1974; 184: 1185-1187.
15. Martuza RL et al. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 1991; 252: 854-856.
16. Jia W et al. Selective destruction of gliomas in immunocompetent rats by thymidine kinase defective herpes simplex virus type-1. J Natl Cancer Inst 1994; 86: 1209-1215.
17. Glorioso JC, Coins WF, Fink DJ, DeLuca NA. Herpes simplex virus vectors and gene transfer to brain (review). Dev Biol Standard 1994; 82: 79-87.
18. Fawl R, Roizman B. Induction of reactivation of herpes simplex virus in murine sensory ganglia in vivo by cadmium. J Virol 1993; 67: 7025-7031.
19. Goldstein D, Weller S. Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6dlacZ insertion mutant. J Virol 1988; 62: 196-205.
20. Sanders PG, Wilkie NM, Davison AJ. Thymidine kinase deletion mutants of herpes simplex virus type 1. J Gen Virol 1982; 63: 277-295.
21. De Clercq E. Antivirals for the treatment of herpes virus infections (review). J Antimicrob Chemother 1993; 32 (Suppl. A): 121-132.
22. Rearing MR. Antiviral agents. Mayo Clin Proc 1992; 67: 160-178.
23. Jacobson J et al. A herpes simplex virus ribonucleotide reductase deletion mutant is defective for productive acute and reactivatable latent infections of mice and for replication in mouse cells. Virology 1989; 173: 276-283.
24. Idowu A, Fraser-Smith E, Poffenberger K, Herman R. Deletion of the herpes simplex virus type 1 ribonucleotide reductase gene alters virulence and latency in vivo. Antir Res 1992; 17: 145-156.
25. Kaplitt MG et al. Mutant herpes simplex virus induced regression of tumors growing in immunocompetent rats. J NeuroOncol 1994; 19: 137-147.
26. Boviatsis EJ et al. Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase. Gene Therapy 1994; 1: 323-331
27. Mineta T, Rabkin SD, Martuza RL. Treatment of malignant gliomas using ganciclovir hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res 1994; 54- 3963-3966.
28. Samaniego LA, Webb AL, DeLuca NA. Functional interactions between herpes simplex virus immediate - early proteins during infection: gene expression as a consequence of ICP27 and different domains of ICP4. J Virol 1995; 69: 5705-5715.
29. Cabrera CV et al. Herpes simplex virus DNA sequences in the CNS of latently infected mice. Nature 1980, 288: 288-290.
30. Efstathiou S et al. Detection of herpes simplex virus-specific DNA sequences in latently infected mice and in humans. J Virol 1986; 57: 446-455.